Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
about
The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulationsBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trialsBeta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.Combination therapy for treatment of infections with gram-negative bacteria.Survey of acute renal failure in patients with cystic fibrosis in the UK.Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.Modulation of antibiotic resistance in Pseudomonas aeruginosa by ZnO nanoparticles.
P2860
Q28485988-0C3A8A22-3050-4384-BFF2-57993031177DQ30756968-EB98EE96-A566-4A1E-AD75-6E77D74A5881Q31143077-0A588E24-F1C3-4926-9A6A-0F6A56E54F52Q33692063-9D6E0837-8E8F-4ED5-9FD6-60F678CAD99AQ36156077-418B789B-68C3-42A8-AC97-32334E79C247Q36225726-0ECF18FA-363F-4607-8982-B30C13201FCFQ36853968-FAB7595A-C0E4-4A31-B27D-57EC112A796FQ40345173-8CCD5EC4-7298-4A07-945A-FE1C7833B027Q41679497-8113234C-5526-4AAC-BB0B-BB2034AB5212Q41858894-33BDEE72-1A78-43F9-8BFE-555FBD3066DEQ42004511-C3155F53-274B-44FE-B1F5-21621CA707DAQ42722312-EDC13D22-BEFA-42D8-9901-835F7E265FB4
P2860
Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@ast
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@en
type
label
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@ast
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@en
prefLabel
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@ast
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@en
P2093
P2860
P1476
Synergism between tobramycin a ...... n vitro pharmacokinetic model.
@en
P2093
Horrevorts AM
Verbrugh HA
den Hollander JG
van Goor ML
P2860
P304
P407
P577
1997-01-01T00:00:00Z